Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Diabetes Metab Syndr Obes. 2009 Jul 1;2:51-60.

Risk management in the treatment of type 2 diabetes with pioglitazone.

Author information

  • 1Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.

Abstract

INTRODUCTION:

Type 2 diabetes mellitus is one of the most important cardiovascular risk factors. Insulin-resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Pioglitazone is an insulin-sensitizing agent available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of pioglitazone in achieving metabolic control and reducing cardiovascular morbidity and mortality.

AIM:

The purpose of this article is to review the effectiveness and tolerability of pioglitazone in the prevention and management of atherosclerosis in patients with type 2 diabetes.

EVIDENCE REVIEW:

We reviewed the main monotherapy and comparative studies of pioglitazone, and particularly the recent evidence in the field of atherosclerosis and cardiovascular prevention.

PLACE IN THERAPY:

The current evidence shows that pioglitazone is an effective option in the treatment of type 2 diabetes. More studies are needed to establish a role for pioglitazone in atherosclerosis prevention beyond glycemic control.

KEYWORDS:

cardiovascular prevention; diabetes mellitus; glycated hemoglobin; pioglitazone

PMID:
21437118
[PubMed]
PMCID:
PMC3048017
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk